(Q44225016)

1 December 2017

title

Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy (English)

1 reference

1 December 2017

1 reference

1 reference

10

Hiromitsu Kumada

1 reference

1 December 2017

1

Fumitaka Suzuki

1 reference

1 December 2017

9

Kenji Ikeda

1 reference

1 December 2017

6

Masahiro Kobayashi

1 reference

1 December 2017

2

Yoshiyuki Suzuki

1 reference

1 December 2017

4

Norio Akuta

1 reference

1 December 2017

8

Yasuji Arase

1 reference

1 December 2017

7

Satoshi Saitoh

1 reference

1 December 2017

5

Takashi Someya

1 reference

1 December 2017

Akihito Tsubota

3

1 reference

1 December 2017

publication date

1 December 2002

1 reference

1 December 2017

published in

Journal of Hepatology

1 reference

1 December 2017

volume

37

1 reference

1 December 2017

issue

6

1 reference

1 December 2017

page(s)

824-830

1 reference

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Long-term follow-up of chronic hepatitis B patients treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900281-7

7 January 2021

10.1016/S0168-8278(02)00281-7

Identifiers

DOI

1 reference

1 December 2017

1 reference